PARIS: Sanofi announced the acquisition of 2.3% of its shares from long-term shareholder L’Oréal as part of its share buyback program initiated on Jan. 30, 2025. The move aligns with Sanofi’s capital allocation strategy and commitment to sustainable value creation…
PARIS, FRANCE: Sanofi, a global leader in healthcare, announced today its financial results for the year 2023, showing a 5.3% increase in sales and a 5.4% increase in business earnings per share (EPS) at constant exchange rates (CER). The company…
PARIS, FRANCE: Sanofi, a global pharmaceutical company, has agreed to acquire Inhibrx, a clinical-stage biotech firm, for $30.0 per share in cash, or about $1.7 billion. The deal is subject to the spin-off of non-INBRX-101 assets into a new entity,…
PARIS, FRANCE: Sanofi, a global biopharmaceutical company, announced today the appointment of three new members to its Executive Committee and the departure of one of its senior leaders. Houman Ashrafian, a renowned scientist and investor, will join Sanofi as Head…
PARIS, FRANCE: Sanofi announced today that it has entered into a definitive agreement to acquire ownership of Qunol, a U.S.-based, market-leading brand in health & wellness, focusing on the active ‘healthy aging’ segment. Qunol offers CoQ10 and Turmeric products that…
PARIS, FRANCE: Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals Inc, an immune-oncology company. Amunix’s pipeline, which includes lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer…
VIENNA, AUSTRIA: Sanofi has entered into an agreement to acquire Origimm Biotechnology GmbH, a news release said. Origimm Biotechnology is an Austrian privately owned biotechnology company specializing in the discovery of virulent skin microbiome components and antigens from bacteria causing…
PARIS, FRANCE: Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus…
LONDON, UK: Sanofi, a global biopharmaceutical company, has committed to invest up to $60 million in equity of Gyroscope Therapeutics Holdings. Gyroscope plans to use proceeds from this investment to support funding of ongoing clinical trials of GT005 in GA….
PARIS: Sanofi announced a €400 million investment over five years to create a unique vaccine production center in Singapore. In partnership with the Singapore Economic Development Board (EDB), the new site will mainly supply the Asian region and complement existing…
LONDON: Schroder UK Public Private Trust (SUPP) has sold of its shares in Kymab Group Ltd. to Sanofi against initial proceeds of approximately US$82 million. Furthermore, the SUPP has the potential for additional contingent payments of up to US$33 million…
PARIS: Sanofi, Capgemini, Generali and Orange are forming a joint venture in France to fast-track the development of concrete healthcare solutions and to make them available to the market for the benefit of patients, a news release said. The project,…